Biotech

All Articles

AstraZeneca messages data on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early take a look at the performance of its own internal anti...

iTeos- GSK's TIGIT star shows purposeful remodeling

.After declaring a stage 3 launch based on beneficial midstage results, iTeos as well as GSK are act...

More collective FDA can speed up rare ailment R&ampD: record

.The FDA ought to be actually a lot more open as well as collaborative to discharge a surge in appro...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It is actually an abnormally busy Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bicar...

Atea's COVID antiviral falls short to stop hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has failed one more COVID-19 trial, however the biotech still store...

Neurocrine's quote to conserve mental illness prospect falls short

.Neurocrine Biosciences' mental illness course pivot has actually stopped working. The biotech was u...

Sanofi spends $110M upfront for late-stage radioligand treatment

.Sanofi has actually created an overdue entry to the radioligand celebration, paying for 100 thousan...

F 2G brings up $100M for second try to receive new antifungal to market

.After F2G's 1st attempt to receive a new lesson of antifungal to market was thwarted by the FDA, th...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 plans among profitability stress

.Moderna has sworn to reduce R&ampD investing through $1.1 billion by 2027. The selection to shrink ...

Sanofi's $80M bank on Fulcrum dystrophy medicine finishes in period 3 go bust

.Merely 4 months after Sanofi wager $80 thousand in upfront money on Pivot Therapeutics' losmapimod,...